Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic
Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a phase 3 trial aimed at treating patients with treatment-resistant depression. The trial’s results revealed that esketamine did not meet its primary endpoint, sparking concern among industry experts and stakeholders. The late-stage study assessed the efficacy of two […]